LeMaitre Vascular (NASDAQ:LMAT) Issues Earnings Results

LeMaitre Vascular (NASDAQ:LMAT) issued its quarterly earnings results on Thursday. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.05, Zacks reports. The firm had revenue of $61.05 million for the quarter, compared to analyst estimates of $62.18 million. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The company’s revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.49 earnings per share. LeMaitre Vascular updated its FY 2025 guidance to 2.480-2.530 EPS and its Q4 2025 guidance to 0.640-0.690 EPS.

LeMaitre Vascular Trading Down 0.8%

Shares of LMAT stock opened at $85.60 on Friday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96. The company has a market capitalization of $1.94 billion, a price-to-earnings ratio of 41.55, a PEG ratio of 2.29 and a beta of 0.77. LeMaitre Vascular has a 52-week low of $71.42 and a 52-week high of $109.58. The company has a 50-day simple moving average of $89.75 and a two-hundred day simple moving average of $87.00.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 4th. Investors of record on Thursday, November 20th will be issued a dividend of $0.20 per share. The ex-dividend date is Thursday, November 20th. This represents a $0.80 annualized dividend and a yield of 0.9%. LeMaitre Vascular’s payout ratio is 38.83%.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Cantor Fitzgerald raised their price target on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Barrington Research restated an “outperform” rating and set a $95.00 price objective on shares of LeMaitre Vascular in a report on Wednesday, October 15th. Roth Capital reissued a “buy” rating and issued a $108.00 price target on shares of LeMaitre Vascular in a research report on Wednesday. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and an average target price of $100.60.

Insider Buying and Selling

In other LeMaitre Vascular news, Director John A. Roush sold 6,561 shares of the company’s stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.55, for a total value of $607,220.55. Following the completion of the transaction, the director owned 2,916 shares in the company, valued at $269,875.80. This represents a 69.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David B. Roberts sold 10,815 shares of the firm’s stock in a transaction on Monday, August 11th. The shares were sold at an average price of $92.39, for a total value of $999,197.85. Following the sale, the director directly owned 17,976 shares of the company’s stock, valued at approximately $1,660,802.64. This represents a 37.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 9.50% of the stock is owned by insiders.

Hedge Funds Weigh In On LeMaitre Vascular

Several institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. raised its position in LeMaitre Vascular by 27.0% in the first quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock worth $22,019,000 after acquiring an additional 55,804 shares during the period. Ameriprise Financial Inc. increased its stake in shares of LeMaitre Vascular by 14.1% during the 2nd quarter. Ameriprise Financial Inc. now owns 231,282 shares of the medical instruments supplier’s stock worth $19,208,000 after purchasing an additional 28,556 shares during the last quarter. Millennium Management LLC raised its holdings in shares of LeMaitre Vascular by 119.8% in the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after purchasing an additional 115,141 shares during the period. Qube Research & Technologies Ltd lifted its stake in LeMaitre Vascular by 7.0% in the second quarter. Qube Research & Technologies Ltd now owns 173,839 shares of the medical instruments supplier’s stock valued at $14,437,000 after purchasing an additional 11,416 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in LeMaitre Vascular by 30.5% during the second quarter. Bank of America Corp DE now owns 115,263 shares of the medical instruments supplier’s stock valued at $9,573,000 after purchasing an additional 26,966 shares during the period. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.